Sangamo Biosciences (SGMO) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil rally pressures S&P, Nasdaq; Microsoft, Salesforce buoy Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Getty Images to go private via prepackaged Chapter 11 restructuring
- Lumentum shares fall after hitting 52-week high
Janney Montgomery Scott Downgrades Sangamo BioSciences (SGMO) to Neutral
August 4, 2016 7:25 AM EDTJanney Montgomery Scott downgraded Sangamo BioSciences (NASDAQ: SGMO) from Buy to Neutral with a price target of $8.00 (from $15.00).
For an analyst ratings summary and ratings history on Sangamo BioSciences click here. For more ratings news on Sangamo BioSciences click here.
Shares of Sangamo BioSciences closed at $6.84 yesterday.
... More


